US10000523B2ActiveUtilityPatentIndex 94
β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
Est. expiryMar 6, 2035(~8.7 yrs left)· nominal 20-yr term from priority
A61P 31/14C07H 19/20A61K 31/7076C07H 19/16C07H 19/207
94
PatentIndex Score
20
Cited by
288
References
30
Claims
Abstract
A compound of the structure: or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.
Claims
exact text as granted — not AI-modifiedWe claim:
1. A pharmaceutical composition comprising an anti-HCV effective amount of a compound of the formula:
in a pharmaceutically acceptable carrier.
2. The pharmaceutical composition of claim 1 , comprising an effective amount of a compound of the formula:
3. The pharmaceutical composition of claim 1 , comprising an effective amount of a compound of the formula:
4. The pharmaceutical composition of claim 1 , in a dosage form.
5. The pharmaceutical composition of claim 4 , in an oral dosage form.
6. The pharmaceutical composition of claim 5 , in a tablet.
7. The pharmaceutical composition of claim 5 , in a capsule.
8. The pharmaceutical composition of claim 2 , in a dosage form.
9. The pharmaceutical composition of claim 8 , in an oral dosage form.
10. The pharmaceutical composition of claim 9 , in a tablet.
11. The pharmaceutical composition of claim 9 , in a capsule.
12. The pharmaceutical composition of claim 3 , in a dosage form.
13. The pharmaceutical composition of claim 12 , in an oral dosage form.
14. The pharmaceutical composition of claim 13 , in a tablet.
15. The pharmaceutical composition of claim 13 , in a capsule.
16. A pharmaceutical composition comprising an anti-HCV effective amount of a compound of the formula:
in a pharmaceutically acceptable carrier.
17. The pharmaceutical composition of claim 16 , comprising an effective amount of a compound of the formula:
18. The pharmaceutical composition of claim 16 , comprising an effective amount of a compound of the formula:
19. The pharmaceutical composition of claim 16 , in a dosage form.
20. The pharmaceutical composition of claim 19 , in an oral dosage form.
21. The pharmaceutical composition of claim 20 , in a tablet.
22. The pharmaceutical composition of claim 20 , in a capsule.
23. The pharmaceutical composition of claim 17 , in a dosage form.
24. The pharmaceutical composition of claim 23 , in an oral dosage form.
25. The pharmaceutical composition of claim 24 , in a tablet.
26. The pharmaceutical composition of claim 24 , in a capsule.
27. The pharmaceutical composition of claim 18 , in a dosage form.
28. The pharmaceutical composition of claim 27 , in an oral dosage form.
29. The pharmaceutical composition of claim 28 , in a tablet.
30. The pharmaceutical composition of claim 28 , in a capsule.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.